Thomas A. Hope1, Rizwan Aslam2, Carlos U. Corvera3, Alex Monto4, Judy Yee2, Benjamin M. Yeh2
1Radiology and Biomedical Imaging, UCSF, San Francisco, CA, United States; 2Radiology, SFVA, San Francisco, CA, United States; 3Surgery, UCSF, San Francisco, CA, United States; 4Gastroenterology, UCSF, San Francisco, CA, United States
We prospectively studied the utility of gadoxetate for the further evaluation of equivocal lesions on CT in patients with cirrhosis. We enrolled 25 patients who had indeterminate lesions on CT. These patients subsequently underwent liver MRI using gadoxetate within two weeks of the CT examination. 32 lesions in 25 patients were imaged. After the administration of Eovist, 13 lesions were downgraded, 11 lesions were upgraded and 8 lesions retained the same grade. In this interim report, gadoxetate appears to aid in the evaluation of indeterminate lesions. Additional follow-up needs to be performed, and goal enrollment is 50 patients.